Manipulating L1CAM-CAR T cells with CRISPR/Cas9 to knock out SELPLG expression or enhance SH2D2A expression did not affect CAR T cell functions necessary for anti-tumor activity in vitro. This evidence concerns the gene L1CAM and neoplasm.